Skip to main content
Erschienen in: Intensive Care Medicine 4/2013

01.04.2013 | Original

Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients

verfasst von: Mario Tumbarello, Gennaro De Pascale, Enrico Maria Trecarichi, Teresa Spanu, Federica Antonicelli, Riccardo Maviglia, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli

Erschienen in: Intensive Care Medicine | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our aim was to identify the clinical profile of intensive care unit (ICU) patients with Pseudomonas aeruginosa (PA) pneumonia and the impact on ICU mortality and duration of mechanical ventilation (MV) of multidrug resistance (MDR) in the PA isolate and inadequate initial antibiotic therapy (IIAT).

Methods

We conducted a retrospective analysis of data prospectively collected in the 18-bed general ICU of a major teaching hospital in Rome, Italy. The study cohort consisted of 110 adult patients with culture-confirmed PA pneumonia consecutively diagnosed in 2008–2010. ICU survivor and nonsurvivor groups were compared to identify factors associated with ICU mortality.

Results

In 42 (38 %) of the 110 cases of PA pneumonia analyzed, the PA isolate was MDR. Fifty-six (50.9 %) of the patients received IIAT, and 49 (44.5 %) died in ICU. In logistic regression analysis, IIAT, diabetes mellitus, higher Simplified Acute Physiology Score (SAPS) II scores, and older age were independently associated with ICU mortality. Among survivors, those who received IIAT or had MDR PA pneumonia had significantly longer median (interquartile ranges, IQR) periods of post-pneumonia onset MV (16.5 [14.5–20] and 15 [12–18] days, respectively) compared with those whose initial therapy was adequate (8 [6–13] days, P < 0.001) and those whose infections were caused by non-MDR PA (10.5 [6.5–13] days, P = 0.01).

Conclusions

Our findings highlight the importance of IIAT as a risk factor for mortality in ICU patients with PA pneumonia. MDR in the PA isolate, like IIAT, can significantly increase the need for MV.
Literatur
1.
Zurück zum Zitat Goossens H (2003) Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 9:980–983PubMedCrossRef Goossens H (2003) Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 9:980–983PubMedCrossRef
2.
Zurück zum Zitat Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK, Canadian Critical Care Trials Group (2008) Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 23:18–26PubMedCrossRef Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, Heyland DK, Canadian Critical Care Trials Group (2008) Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 23:18–26PubMedCrossRef
3.
Zurück zum Zitat Jones RN (2010) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(Suppl 1):S81–S87PubMedCrossRef Jones RN (2010) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(Suppl 1):S81–S87PubMedCrossRef
4.
Zurück zum Zitat Torres A, Ewig S, Lode H, Carlet J (2009) Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 35:9–29PubMedCrossRef Torres A, Ewig S, Lode H, Carlet J (2009) Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 35:9–29PubMedCrossRef
5.
Zurück zum Zitat Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578PubMedCrossRef Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578PubMedCrossRef
6.
Zurück zum Zitat Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y (2010) In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 36:513–522PubMedCrossRef Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y (2010) In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 36:513–522PubMedCrossRef
7.
Zurück zum Zitat Sun HY, Fujitani S, Quintiliani R, Yu VL (2011) Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 139:1172–1185PubMedCrossRef Sun HY, Fujitani S, Quintiliani R, Yu VL (2011) Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 139:1172–1185PubMedCrossRef
8.
Zurück zum Zitat Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, DE Pascale G, Parisini A, Rossi M, Molinari MP, Spanu T, Viscoli C, Cauda R, Bassetti M (2011) Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 139:1740–1749PubMedCrossRef Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, DE Pascale G, Parisini A, Rossi M, Molinari MP, Spanu T, Viscoli C, Cauda R, Bassetti M (2011) Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 139:1740–1749PubMedCrossRef
9.
Zurück zum Zitat Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH (2008) Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134:281–287PubMedCrossRef Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH (2008) Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134:281–287PubMedCrossRef
10.
Zurück zum Zitat Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J (2007) Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 35:1888–1895PubMedCrossRef Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J (2007) Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 35:1888–1895PubMedCrossRef
11.
Zurück zum Zitat Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C (1993) Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94:281–288PubMedCrossRef Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C (1993) Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 94:281–288PubMedCrossRef
12.
Zurück zum Zitat Montravers P, Fagon JY, Chastre J, Lecso M, Dombret MC, Trouillet JL, Gibert C (1993) Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 147:38–44PubMedCrossRef Montravers P, Fagon JY, Chastre J, Lecso M, Dombret MC, Trouillet JL, Gibert C (1993) Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 147:38–44PubMedCrossRef
13.
Zurück zum Zitat Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B, Outcomerea Study Group (2006) Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 129:110–117PubMedCrossRef Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B, Outcomerea Study Group (2006) Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 129:110–117PubMedCrossRef
14.
Zurück zum Zitat Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J (2009) Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother 43:28–35PubMedCrossRef Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J (2009) Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother 43:28–35PubMedCrossRef
15.
Zurück zum Zitat Kaminski C, Timsit JF, Dubois Y, Zahar JR, Garrouste-Orgeas M, Vesin A, Azoulay E, Feger C, Dumenil AS, Adrie C, Cohen Y, Allaouchiche B, OUTCOMEREA study group (2011) Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care 15:R112PubMedCrossRef Kaminski C, Timsit JF, Dubois Y, Zahar JR, Garrouste-Orgeas M, Vesin A, Azoulay E, Feger C, Dumenil AS, Adrie C, Cohen Y, Allaouchiche B, OUTCOMEREA study group (2011) Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care 15:R112PubMedCrossRef
16.
Zurück zum Zitat Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J (2006) Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 32:1970–1978PubMedCrossRef Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J (2006) Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 32:1970–1978PubMedCrossRef
17.
Zurück zum Zitat Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34:1047–1054PubMedCrossRef Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34:1047–1054PubMedCrossRef
18.
Zurück zum Zitat El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K (2008) Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 178:513–519PubMedCrossRef El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K (2008) Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 178:513–519PubMedCrossRef
19.
Zurück zum Zitat Giantsou E, Manolas K (2011) Superinfections in Pseudomonas aeruginosa ventilator-associated pneumonia. Minerva Anestesiol 77:964–970PubMed Giantsou E, Manolas K (2011) Superinfections in Pseudomonas aeruginosa ventilator-associated pneumonia. Minerva Anestesiol 77:964–970PubMed
20.
Zurück zum Zitat Venier AG, Gruson D, Lavigne T, Jarno P, L’hériteau F, Coignard B, Savey A, Rogues AM, REA-RAISIN group (2011) Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN. J Hosp Infect 79:44–48PubMedCrossRef Venier AG, Gruson D, Lavigne T, Jarno P, L’hériteau F, Coignard B, Savey A, Rogues AM, REA-RAISIN group (2011) Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN. J Hosp Infect 79:44–48PubMedCrossRef
21.
Zurück zum Zitat Rello J, Allegri C, Rodriguez A, Vidaur L, Sirgo G, Gomez F, Agbaht K, Pobo A, Diaz E (2006) Risk factors for ventilator-associated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposure. Anesthesiology 105:709–714PubMedCrossRef Rello J, Allegri C, Rodriguez A, Vidaur L, Sirgo G, Gomez F, Agbaht K, Pobo A, Diaz E (2006) Risk factors for ventilator-associated pneumonia by Pseudomonas aeruginosa in presence of recent antibiotic exposure. Anesthesiology 105:709–714PubMedCrossRef
22.
Zurück zum Zitat Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM (1991) Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 143:1121–1129PubMed Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM (1991) Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 143:1121–1129PubMed
23.
Zurück zum Zitat Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRef Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRef
24.
Zurück zum Zitat Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758PubMedCrossRef Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758PubMedCrossRef
25.
Zurück zum Zitat Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Eighteenth Informational Supplement. 2008, M100-S18. Wayne, PA Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Eighteenth Informational Supplement. 2008, M100-S18. Wayne, PA
26.
Zurück zum Zitat Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296–327PubMedCrossRef Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296–327PubMedCrossRef
27.
Zurück zum Zitat Fujitani S, Sun HY, Yu VL, Weingarten JA (2011) Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 139:909–919PubMedCrossRef Fujitani S, Sun HY, Yu VL, Weingarten JA (2011) Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 139:909–919PubMedCrossRef
28.
Zurück zum Zitat Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW (2010) Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54:3717–3722PubMedCrossRef Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW (2010) Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54:3717–3722PubMedCrossRef
29.
Zurück zum Zitat Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11:68–74PubMedCrossRef Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11:68–74PubMedCrossRef
30.
Zurück zum Zitat Damas P, Layios N, Seidel L, Nys M, Melin P, Ledoux D (2011) Severity of ICU-acquired pneumonia according to infectious microorganisms. Intensive Care Med 37:1128–1135PubMedCrossRef Damas P, Layios N, Seidel L, Nys M, Melin P, Ledoux D (2011) Severity of ICU-acquired pneumonia according to infectious microorganisms. Intensive Care Med 37:1128–1135PubMedCrossRef
31.
Zurück zum Zitat Kuti EL, Patel AA, Coleman CI (2008) Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 23:91–100PubMedCrossRef Kuti EL, Patel AA, Coleman CI (2008) Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care 23:91–100PubMedCrossRef
32.
Zurück zum Zitat Vincent JL (2000) Microbial resistance: lessons from the EPIC study. European Prevalence of Infection. Intensive Care Med 26(Suppl 1):S3–S8PubMedCrossRef Vincent JL (2000) Microbial resistance: lessons from the EPIC study. European Prevalence of Infection. Intensive Care Med 26(Suppl 1):S3–S8PubMedCrossRef
33.
Zurück zum Zitat Nordmann P, Naas T, Poirel L (2011) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798PubMedCrossRef Nordmann P, Naas T, Poirel L (2011) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798PubMedCrossRef
34.
Zurück zum Zitat Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22th Informational Supplement. 2012, M100-S22. Wayne, PA Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 22th Informational Supplement. 2012, M100-S22. Wayne, PA
35.
Zurück zum Zitat Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52:813–821PubMedCrossRef Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52:813–821PubMedCrossRef
36.
Zurück zum Zitat Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, De Pascale G, Proli EM, Cauda R, Cicchetti A, Fadda G (2010) Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 54:4085–4091PubMedCrossRef Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, De Pascale G, Proli EM, Cauda R, Cicchetti A, Fadda G (2010) Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 54:4085–4091PubMedCrossRef
37.
Zurück zum Zitat Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA (2010) Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 54:109–115PubMedCrossRef Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA (2010) Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 54:109–115PubMedCrossRef
38.
Zurück zum Zitat Shorr AF, Combes A, Kollef MH, Chastre J (2006) Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 34:700–706PubMedCrossRef Shorr AF, Combes A, Kollef MH, Chastre J (2006) Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 34:700–706PubMedCrossRef
39.
Zurück zum Zitat Shorr AF, Micek ST, Kollef MH (2008) Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 36:2335–2340PubMedCrossRef Shorr AF, Micek ST, Kollef MH (2008) Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 36:2335–2340PubMedCrossRef
40.
Zurück zum Zitat Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH (2011) Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 39:46–51PubMedCrossRef Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH (2011) Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med 39:46–51PubMedCrossRef
Metadaten
Titel
Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients
verfasst von
Mario Tumbarello
Gennaro De Pascale
Enrico Maria Trecarichi
Teresa Spanu
Federica Antonicelli
Riccardo Maviglia
Mariano Alberto Pennisi
Giuseppe Bello
Massimo Antonelli
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 4/2013
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-013-2828-9

Weitere Artikel der Ausgabe 4/2013

Intensive Care Medicine 4/2013 Zur Ausgabe

Imaging in Intensive Care Medicine

Unusual cardiac tamponade

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.